CK2-IN-1

Research use only, not for human use.

CK2-IN-1 is a potent, competitive inhibitor of ATP binding to Casein kinase 2(CK2) with IC50 of 9 nM.

CK2-IN-1 is a potent, competitive inhibitor of ATP binding to Casein kinase 2(CK2) with IC50 of 9 nM, induces differentiation of epidermal progenitor cells to terminally differentiated keratinocytes with EC50 of 0.1 uM.

Treatment of human epidermal keratinocytes (NHEKs) with Casein Kinase II Inhibitor IV leads to an increase in the early differentiation markers keratins 1 and 10 at 48 h. Increased levels of IVL and TGM are observed in cells treated with Casein Kinase II Inhibitor IV at 72 h and persisted at 96 h. In addition, treated with Casein Kinase II Inhibitor IV expressesloricrin, a terminal differentiation marker, at later time points. Similar results are observed by messenger RNA (mRNA) expression analysis of NHEKs treated with Casein Kinase II Inhibitor IV. At early time points (12 and 24 h), treatment with Casein Kinase II Inhibitor IV leads to the upregulation of keratinocyte early differentiation marker genes, including keratin 1 (5.4-fold) and keratin 10 (5.4-fold). Terminal differentiation marker genes, including IVL (1.8-fold), TGM 1 (4.8-fold), loricrin (3.3-fold), and filaggrin (5.6-fold), are upregulated at late time points (36 and 48 h). These results are again consistent with the ability of Casein Kinase II Inhibitor IV to induce differentiation of epidermal progenitor cells into terminally differentiated keratinocytes.

——

——

Metabolic Enzyme/Protease

Casein Kinase

Casein Kinase

Cancer

——

863598-09-8

429.48

C24H23N5O3

>98% (HPLC)

DMSO : ≥ 250 mg/mL 582.11 mM

COC1=CC(=CC(=C1OC)OC)NC2=NC=C3C=CN(C3=N2)C4=CC=CC(=C4)CCC#N

3-(3-(2-((3,4,5-trimethoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)propanenitrile

(-20℃)

With Ice Pack

≥ 2 years